Posts by: jking

Facilitating Innovation at TDRR

Within the scientific community, innovation and progress go hand-in-hand.  New ideas bring with them better technologies and force scientists and businesspeople alike to ask more questions and think outside the box.  Tech, Drugs and Rock & Roll seeks to foster the growth and development of these fresh concepts by creating a entertaining platform from which […]

Improving on the Age-Old Sport of Networking

The key to staying well-connected is through effective networking—making that initial connection is important and but staying in touch with others helps keep one’s extant network dynamic and growing.  As a networking event, Tech, Drugs and Rock & Roll’s main purpose is to facilitate the creation of new connections (or the improvement of old ones) between its participants.  […]

Spotlight On: Lou Pride

This year, Lou Pride will put the “Rock & Roll” in Tech, Drugs and Rock & Roll—the blues singer will perform with Boston University’s own professor of music, Victor Coelho, and put some soul into the entrepreneurial spirit of the event. A Chicago native, Pride sang in the choir of his local church as a […]

Message from the Director: Life Sciences Research at BU

Dear Reader, Boston University (BU) provides about $4 billion in economic impact to Massachusetts annually, including supporting the payroll of about 44,000 jobs. A large portion of this is related to life sciences activities. BU has a medical school and jointly operates Boston Medical Center, which serves Boston’s low-income and minority population. BU is a […]

Targeted Cancer Therapies

Many of today’s oncological therapies take a targeted approach towards combating cancer in order to reduce the amount of collateral damage on the patient’s healthy cells. Since traditional cancer therapies are notorious for their many harmful side-effects, researchers seek to develop therapies that affect only diseased cells. At Boston University, Professors Remco A. Spanjaard and […]

Start-up Profile: Predictus

Incorporated on December 31st of last year, Predictus has developed a companion diagnostic for a class of oncology drugs called topoisomerase 1 (topo1) inhibitors. Meant to address the low response rates of topo1 inhibitor therapy patients, Predictus’ diagnostic will save valuable time for cancer patients and provide a powerful decision tool for physicians. Dr. Ajit […]